Compare ELOG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | LSTA |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 20.9M |
| IPO Year | 2025 | N/A |
| Metric | ELOG | LSTA |
|---|---|---|
| Price | $1.15 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 1.9M | 28.0K |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.27 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $45,962,309.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.22 | ★ N/A |
| Revenue Growth | ★ 10.64 | N/A |
| 52 Week Low | $0.88 | $1.81 |
| 52 Week High | $3.60 | $4.20 |
| Indicator | ELOG | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.16 |
| Support Level | N/A | $1.81 |
| Resistance Level | N/A | $2.17 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 19.44 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.